News
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the first patient in the 48 mg, multiple ascending dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback